International reproducibility study of thymic epithelial tumors staging: pT stage is an issue. proposals for improvement. A RYTHMIC/ITMIG study
The proposals for the T stage of thymic epithelial tumors (TET) in the 8th edition of the UICC/AJCC TNM classification were mainly based on an International Thymic Malignancy Interest Group (ITMIG) worldwide database including patients with available pathologic stage information [1]. In the TNM classification, pT1a stage includes patients with TET limited to the thymus and mediastinal fat, whereas mediastinal pleural invasion is defined as pT1b. pTNM stage further differentiates pericardial invasion (pT2) from lung invasion (pT3). (Source: Lung Cancer)
Source: Lung Cancer - January 23, 2024 Category: Cancer & Oncology Authors: Thierry Jo Molina, Anja C. Roden, Malgorzata Szolkowska, Shigeki Shimizu, Andre L. Moreira, Lara Chalabreysse, Benjamin Besse, Vincent de Montpr éville, Edith M. Marom, Frank Detterbeck, Nicolas Girard, Andrew G. Nicholson, Alexander Marx Source Type: research
Strengths and challenges in current lung cancer care: Timeliness and diagnostic procedures in six Dutch hospitals
In the past two decades, the incidence of lung cancer (LC) in the Netherlands increased to over 14.500 new cases in 2022 [1]. Most patients are diagnosed with advanced or metastatic LC, leading to a 5-year overall survival rate of 19 % [3]. Timely detection of lung cancer is therefore crucial to achieve successful treatment and improved patient outcome [4]. (Source: Lung Cancer)
Source: Lung Cancer - January 21, 2024 Category: Cancer & Oncology Authors: Sylvia A.A.M. Genet, Esther Visser, Maggy Youssef-El Soud, Huub N.A. Belderbos, Gerben Stege, Marleen E.A. de Saegher, Susan C. van 't Westeinde, Luc Brunsveld, Maarten A.C. Broeren, Daan van de Kerkhof, Federica Eduati, Ben E.E.M. van den Borne, Volkher Source Type: research
Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis
Leptomeningeal metastasis (LM) is a lethal complication in patients with non-small cell lung cancer (NSCLC) that leads to a poor prognosis [1,2]. The incidence of LM has been increasing, accounting for 3 –5 % in molecularly unselected NSCLC patients and up to 9–16 % in epidermal growth factor receptor (EGFR)-mutant lung cancer patients [2–4]. This increased incidence may be attributed to the prolonged survival of patients with EGFR-mutated NSCLC owing to the introduction of EGFR-tyrosine k inase inhibitors (TKIs). (Source: Lung Cancer)
Source: Lung Cancer - January 19, 2024 Category: Cancer & Oncology Authors: Haicheng Wu, Qian Zhang, Wanchen zhai, Yunfei Chen, Yehao Yang, Mingning Xie, Zhiyu Huang, Yanjun Xu, Hui Li, Lei Gong, Sizhe Yu, Yun Fan, Kaiyan Chen Source Type: research
A multidisciplinary review of several aspects of Asbestos-Related Lung Cancer (ARLC)
Tobacco remains the dominant risk factor for lung cancer and tends to overshadow the hazards of other air-borne carcinogens. Long latency and lack of accurate asbestos exposure data have considerably delayed the recognition of asbestos as a major lung cancer carcinogen. During the first half of the previous century several clinical observations had suggested that asbestos exposure could be the cause of lung and a novel type of pleural cancer (mesothelioma), but this suspicion was only fully confirmed several years later [1,2]. (Source: Lung Cancer)
Source: Lung Cancer - January 17, 2024 Category: Cancer & Oncology Authors: N. van Zandwijk, Arthur L. Frank Tags: Editorial Source Type: research
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced Non-Small cell lung cancer following Platinum-Based doublet chemotherapy and immunotherapy (CANOPY-2): A Multicenter, Randomized, Double-Blind, phase 3 trial
Platinum-based doublet chemotherapy (PDC) and immune checkpoint inhibitor (ICI) therapy are standard of care for eligible patients with advanced non-small cell lung cancer (NSCLC) without targetable mutations [1]. Patients who progress on these therapies (either in combination or sequentially) have limited treatment options, which include single-agent chemotherapy, such as docetaxel, or combinations, such as docetaxel with the anti-angiogenic agents ramucirumab, nintedanib, or S-1 [1 –4]; however, these treatments provide only modest efficacy. (Source: Lung Cancer)
Source: Lung Cancer - January 15, 2024 Category: Cancer & Oncology Authors: Luis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, Balazs Halmos, Byoung Chul Cho, Manuel Cobo, Jos é Luis González Larriba, Caicun Zhou, Ingel Demedts, Akin Atmaca, Sofia Baka, Bijoyesh Mookerjee, Socorro Portella, Zewen Zhu, Jincheng Wu, David Demanse, Source Type: research
